Randy Schreckhise

Randy has made contributions to a number of approved therapeutics and therapeutic candidates through finance, business development, operations, and strategy roles at aTyr Pharma, Abilita Bio, Trius Therapeutics, Ardea Biosciences, Human Genome Sciences, and ZymoGenetics, and also through work in project management, protein biochemistry and genetics during his eight years at ZymoGenetics. Earlier in his career, he worked in the Basic Sciences and Clinical Divisions at The Fred Hutchinson Cancer Research Center, where he studied meiotic recombination of the fission yeast S. pombe and also developed DNA-based assays for the detection of invasive fungal disease. For the past eight years, Randy has been an active member of The San Diego Entrepreneurs Exchange and currently serves as a Board Member. He received an MBA with a concentration in finance from Seattle University and a BS in microbiology with a minor in molecular biology from Washington State University, where he was a Howard Hughes Undergraduate Research Fellow.